These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

339 related items for PubMed ID: 26511616

  • 1. Treatment outcomes in multidrug resistant tuberculosis-human immunodeficiency virus Co-infected patients on anti-retroviral therapy at Sizwe Tropical Disease Hospital Johannesburg, South Africa.
    Umanah T, Ncayiyana J, Padanilam X, Nyasulu PS.
    BMC Infect Dis; 2015 Oct 28; 15():478. PubMed ID: 26511616
    [Abstract] [Full Text] [Related]

  • 2. Predictors of cure among HIV co-infected multidrug-resistant TB patients at Sizwe Tropical Disease Hospital Johannesburg, South Africa.
    Umanah TA, Ncayiyana JR, Nyasulu PS.
    Trans R Soc Trop Med Hyg; 2015 May 28; 109(5):340-8. PubMed ID: 25787727
    [Abstract] [Full Text] [Related]

  • 3. Risk factors for mortality among adults registered on the routine drug resistant tuberculosis reporting database in the Eastern Cape Province, South Africa, 2011 to 2013.
    Chingonzoh R, Manesen MR, Madlavu MJ, Sopiseka N, Nokwe M, Emwerem M, Musekiwa A, Kuonza LR.
    PLoS One; 2018 May 28; 13(8):e0202469. PubMed ID: 30133504
    [Abstract] [Full Text] [Related]

  • 4. Risk factors for mortality among MDR- and XDR-TB patients in a high HIV prevalence setting.
    Gandhi NR, Andrews JR, Brust JC, Montreuil R, Weissman D, Heo M, Moll AP, Friedland GH, Shah NS.
    Int J Tuberc Lung Dis; 2012 Jan 28; 16(1):90-7. PubMed ID: 22236852
    [Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8. Improved survival in multidrug-resistant tuberculosis patients receiving integrated tuberculosis and antiretroviral treatment in the SAPiT Trial.
    Padayatchi N, Abdool Karim SS, Naidoo K, Grobler A, Friedland G.
    Int J Tuberc Lung Dis; 2014 Feb 28; 18(2):147-54. PubMed ID: 24429305
    [Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10. Outcomes of multidrug-resistant tuberculosis treatment with early initiation of antiretroviral therapy for HIV co-infected patients in Lesotho.
    Satti H, McLaughlin MM, Hedt-Gauthier B, Atwood SS, Omotayo DB, Ntlamelle L, Seung KJ.
    PLoS One; 2012 Feb 28; 7(10):e46943. PubMed ID: 23115633
    [Abstract] [Full Text] [Related]

  • 11. Adherence Measured Using Electronic Dose Monitoring is Associated with Emergent Antiretroviral Resistance and Poor Outcomes in People with Human Immunodeficiency Virus/AIDS and Multidrug-Resistant Tuberculosis.
    Bateman M, Wolf A, Chimukangara B, Brust JCM, Lessells R, Amico R, Boodhram R, Singh N, Orrell C, Friedland G, Naidoo K, Padayatchi N, O'Donnell MR.
    Clin Infect Dis; 2022 Oct 29; 75(9):1489-1496. PubMed ID: 35352097
    [Abstract] [Full Text] [Related]

  • 12. Undertreated HIV and drug-resistant tuberculosis at a referral hospital in Irkutsk, Siberia.
    Heysell SK, Ogarkov OB, Zhdanova S, Zorkaltseva E, Shugaeva S, Gratz J, Vitko S, Savilov ED, Koshcheyev ME, Houpt ER.
    Int J Tuberc Lung Dis; 2016 Feb 29; 20(2):187-92. PubMed ID: 26792470
    [Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14. Risk factors for poor multidrug-resistant tuberculosis treatment outcomes in Kyiv Oblast, Ukraine.
    Aibana O, Bachmaha M, Krasiuk V, Rybak N, Flanigan TP, Petrenko V, Murray MB.
    BMC Infect Dis; 2017 Feb 07; 17(1):129. PubMed ID: 28173763
    [Abstract] [Full Text] [Related]

  • 15. Improved Survival and Cure Rates With Concurrent Treatment for Multidrug-Resistant Tuberculosis-Human Immunodeficiency Virus Coinfection in South Africa.
    Brust JCM, Shah NS, Mlisana K, Moodley P, Allana S, Campbell A, Johnson BA, Master I, Mthiyane T, Lachman S, Larkan LM, Ning Y, Malik A, Smith JP, Gandhi NR.
    Clin Infect Dis; 2018 Apr 03; 66(8):1246-1253. PubMed ID: 29293906
    [Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17. Intensive-phase treatment outcomes among hospitalized multidrug-resistant tuberculosis patients: results from a nationwide cohort in Nigeria.
    Oladimeji O, Isaakidis P, Obasanya OJ, Eltayeb O, Khogali M, Van den Bergh R, Kumar AM, Hinderaker SG, Abdurrahman ST, Lawson L, Cuevas LE.
    PLoS One; 2014 Apr 03; 9(4):e94393. PubMed ID: 24722139
    [Abstract] [Full Text] [Related]

  • 18. Outcomes of comprehensive care for children empirically treated for multidrug-resistant tuberculosis in a setting of high HIV prevalence.
    Satti H, McLaughlin MM, Omotayo DB, Keshavjee S, Becerra MC, Mukherjee JS, Seung KJ.
    PLoS One; 2012 Apr 03; 7(5):e37114. PubMed ID: 22629356
    [Abstract] [Full Text] [Related]

  • 19. Time to ART Initiation among Patients Treated for Rifampicin-Resistant Tuberculosis in Khayelitsha, South Africa: Impact on Mortality and Treatment Success.
    Daniels JF, Khogali M, Mohr E, Cox V, Moyo S, Edginton M, Hinderaker SG, Meintjes G, Hughes J, De Azevedo V, van Cutsem G, Cox HS.
    PLoS One; 2015 Apr 03; 10(11):e0142873. PubMed ID: 26555134
    [Abstract] [Full Text] [Related]

  • 20. Factors associated with mortality among laboratory-diagnosed drug-resistant tuberculosis patients on treatment, KwaZulu-Natal Province, 2017-2019.
    Phafane MP, Ngozo J, Radebe Z, Lutge E, Ebonwu J.
    Pan Afr Med J; 2024 Apr 03; 47():181. PubMed ID: 39092023
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 17.